期刊
VACCINE
卷 30, 期 2, 页码 225-230出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.11.010
关键词
Adjuvant; Vaccine; Immunization; Extra domain-B; Angiogenesis; Cancer
资金
- Swedish Research Council
- Swedish Cancer Society
- Swedish Society of Medicine
- Jeanssonis Foundation
- Ake Wiberg Foundation
We have recently shown that immunization against the extra domain-B (ED-B) of fibronectin, using Freund's adjuvant, reduces tumor growth in mice by 70%. In the present study we compare the immune response generated against ED-B using the non-toxic and biodegradable adjuvant Montanide ISA 720/CpG with the response elicited by Freund's adjuvant. Montanide ISA 720/CpG induced anti-ED-B antibodies with higher avidity and less variable levels between individuals than Freund's. Moreover, the duration of the immune response was longer and the generation of anti-ED-B antibodies in naive mice was faster, when Montanide ISA 720/CpG was used. We conclude that it is possible to replace the mineral oil based adjuvant Freund's with an adjuvant acceptable for human use, which is a prerequisite for transfer of the ED-B vaccine to the clinic. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据